Rezultati pretraživanja
  1. 4. velj
  2. 4. velj

    Hear expert insight and practical strategies for appropriately integrating therapy into treatment plans for patients with leukemia and lymphoma: Join us at in Orlando on February 20th for a MasterClass symposium.

  3. 3. velj

    overviews the challenges that remain in developing and manufacturing therapies in the introduction to BPI's latest Featured Report. Check out her synopsis as well as interviews with key industry players here:

  4. 3. velj

    Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the EBMT and the Joint Accreditation Committee of ISCT and EBMT (JACIE)

  5. 2. velj

    therapy has emerged as a new avenue of treatment for heavily pretreated patients with relapsed/refractory

  6. 1. velj

    Targeting stem cells with . >>> hematopoietic stem cells expressing IL-1RAP can be targeted by chimeric antigen receptor (CAR)-engineered T cells

  7. 1. velj
  8. ~30-minute video on the appropriate use of therapy in hematologic malignancies. [WATCH]: --- -w/ Dr. Sattva Neelapu of & other experts

  9. 31. sij

    Products Among Top Advances in Non-Hodgkin Lymphoma

  10. 31. sij

    The application is supported by findings from the phase II ZUMA-2 trial, in which a single infusion of the therapy led to an overall response rate of 93%, including a 67% complete response rate, in this patient population

  11. 31. sij

    Looks like a very useful article on the development of therapies with a focus on the challenges encountered navigating the regulatory process in Europe and an update on their performance after approval.

  12. 31. sij

    💡: Day 2 of the - 2nd European CAR T Cell Meeting kicks off with a full auditorium in Sitges, Spain! The first keynote of the day was an insightful presentation by Prof Carl June on the latest updates in therapy.

  13. 31. sij
  14. 30. sij
  15. 30. sij
  16. 30. sij
  17. 30. sij

    Penn researchers identify cancer cell defect driving resistance to therapy –

  18. 30. sij

    What about $SRNE’s CD38 program and/or the CEA CAR program it ripped off of my company? Have they disclosed the RV packaging plasmid issue on the CEA program yet? Spoiler: no. They have no business taking on any new programs, and they certainly aren’t virologists!

    Prikaži ovu nit
  19. 30. sij

    Packed house at the EBMT CAR-T cell meeting in Spain. .

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.